KEYNOTE-B98: Phase Ib/II study of pembrolizumab plus investigational agents as second-line treatment for anti-PD-1/PD-L1-refractory extensive-stage small cell lung cancer (ES-SCLC)

被引：0
|
作者：
Lai, W. C. V. [1 ]
Ahn, M-J. [2 ]
Shentzer, T. [3 ]
Kowalski, D. [4 ]
Cho, B. C. [5 ]
Schmid, S. [6 ]
Jove, M. [7 ]
Huang, M. [8 ]
Zhao, B. [8 ]
El-Osta, H. [8 ]
Navarro, A. [9 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Med Oncol, 1275 York Ave, New York, NY 10021 USA
[2] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
[3] Rambam Med Ctr, Dept Med Oncol, Haifa, Israel
[4] Maria Sklodowska Curie Natl Res Inst Oncol, Dept Med Oncol, Warsaw, Poland
[5] Yonsei Univ, Yonsei Canc Ctr, Coll Med, Seoul, South Korea
[6] Kantonsspital St Gallen, Dept Med Oncol, St Gallen, Switzerland
[7] Inst Catala Oncol, Barcelona, Spain
[8] Merck & Co Inc, Kenilworth, NJ USA
[9] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.10.134
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
116TiP
引用
收藏
页码：S1425 / S1426
页数：2
相关论文
共 50 条
  • [1] Results from KEYNOTE-B98: A phase 1b/2 study of pembrolizumab plus investigational agents in patients with anti-PD-(L)1-refractory extensive-stage small-cell lung cancer (ES-SCLC)
    Navarro, Alejandro
    Ahn, Myung-Ju
    Stevenson, James
    Peled, Nir
    Kutiel, Talia Shentzer
    Huemer, Florian
    Kim, Dong-Wan
    Casulleras, Maria Jove
    Khattak, Adnan
    Kowalski, Dariusz
    Leighl, Natasha B.
    de Marinis, Filippo
    Lips, Carolin
    Niu, Jiaxin
    Huang, Mo
    Zhao, Bin
    El-Osta, Hazem
    Owonikoko, Taofeek
    CANCER RESEARCH, 2024, 84 (07)
  • [2] KEYNOTE-B99: Phase II study of pembrolizumab plus investigational agents combined with chemotherapy as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC)
    Peled, N.
    Rodriguez-Abreu, D.
    Bordoni, R.
    Ellis, P. M.
    Hochmair, M.
    Mueller, V.
    Levchenko, E.
    Zhou, H.
    Zhao, B.
    Lara-Guerra, H.
    Ahn, M-J.
    ANNALS OF ONCOLOGY, 2021, 32 : S1425 - S1425
  • [3] Results from KEYNOTE-B99: Phase 2 study of first-line (1L) pembrolizumab (pembro) plus investigational agents and chemotherapy (chemo) for extensive-stage small-cell lung cancer (ES-SCLC)
    Rodriguez-Abreu, Delvys
    Hochmair, Maximillian
    Cho, Byoung Chul
    Csoszi, Tibor
    Kutiel, Talia Shentzer
    Mueller, Veronika
    Ahn, Myung-Ju
    Kowalski, Dariusz
    Maio, Michele
    Moiseyenko, Vladimir
    Navarro, Alejandro
    Niu, Jianxin
    Fung, Andrea S.
    Lips, Carolin
    Zhou, Heng
    Zhao, Bin
    Lara-Guerra, Humberto
    Peled, Nir
    CANCER RESEARCH, 2024, 84 (07)
  • [4] COMPARATIVE EFFECTIVENESS MODELING OF AN ANTI-PD-1 ANTIBODY DRUG INTERVENTION FOR PATIENTS WITH EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC) IN THE US
    Ventura, N.
    VALUE IN HEALTH, 2024, 27 (06) : S153 - S153
  • [5] PD-(L)1 inhibitors plus anlotinib: A superior option for second-line treatment of extensive-stage small cell lung cancer.
    Zhang, Jian
    Sun, Yuping
    Gao, Qin Ai
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] Tifcemalimab combined with toripalimab and chemotherapy as 1st line treatment for extensive-stage small cell lung cancer (ES-SCLC): A phase Ib/II, open-label study
    Yu, Yongfeng
    Yu, Yan
    Zhang, Yan
    Zhang, Wei
    Lv, Dongqing
    Chen, Yuan
    Huang, Dingzhi
    Zhang, Mingjun
    Li, Yongsheng
    Li, Dairong
    Gao, Junzhen
    Wu, Lin
    He, Zhiyong
    Shi, Jianhua
    Zhao, Mingfang
    Liu, Anwen
    Wang, Chunyue
    Zhu, Hui
    Lu, Shun
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [7] Second-line treatment outcomes following first-line chemotherapy plus immunotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC): A multicenter study.
    Pons-Tostivint, Elvire
    Ezzedine, Remy
    Goronflot, Thomas
    Crequit, Perrine
    Chatellier, Thierry
    Raimbourg, Judith
    Bennouna, Jaafar
    Leprieur, Etienne Giroux
    Porte, Marie
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] Second-line treatment outcomes after first-line chemotherapy plus immunotherapy in Extensive-Stage small cell lung cancer (ES-SCLC) patients: A large French multicenter study
    Pons-Tostivint, Elvire
    Ezzedine, Remy
    Goronflot, Thomas
    Crequit, Perrine
    Chatellier, Thierry
    Raimbourg, Judith
    Bennouna, Jaafar
    Leprieur, Etienne Giroux
    Porte, Marie
    LUNG CANCER, 2024, 194
  • [9] Outcomes of anti-PD-L1 blockades plus etoposide and platinum (EP) as first-line therapy for extensive-stage small-cell lung cancer (ES-SCLC) with brain metastasis (BM).
    Tian, Yaru
    Ma, Ji
    Zhu, Hui
    Yu, Jinming
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [10] Patterns of treatment failure for PD-(L)1 refractory extensive-stage small cell lung cancer in continued PD-(L)1 treatment
    Liu, Li
    Liu, Tong
    Wang, Xingwen
    Wang, Jianbo
    Wang, Jun
    Yuan, Meng
    Yang, Yunxin
    Zhang, Yingying
    Wang, Hang
    Hu, Pingping
    Zhang, Jiandong
    TRANSLATIONAL ONCOLOGY, 2023, 33
12345